Status:
COMPLETED
Provoked Craving Assessment
Lead Sponsor:
GlaxoSmithKline
Conditions:
Smoking Dependence
Smoking
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Evaluation of the ability of a nicotine mini lozenge to provide early relief of craving for a cigarette in smokers
Eligibility Criteria
Inclusion
- Current cigarette smokers who have smoked regularly, and smoke more than 20 cigarettes per day on a regular basis for at least a year;
- Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history.
Exclusion
- Any disease that may interfere with the absorption, metabolism or excretion of the study product.
- A medical condition that might jeopardise the safety of the subject or the validity of the study results. For example, recent myocardial infarction or cerebrovascular incident (within 12 weeks of the screening visit), phenylketonuria, unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT01506908
Start Date
September 1 2011
End Date
December 1 2011
Last Update
August 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles Clinical Trials
Burbank, California, United States, 91505